HAS-BLED
HAS-BLED is a clinical prediction rule used to estimate the risk of major bleeding for patients on anticoagulation for atrial fibrillation (AF). It is often used in conjunction with the CHA2DS2-VASc score, which estimates the risk of stroke in patients with AF. The HAS-BLED score is calculated based on the presence of certain risk factors, each of which contributes one point to the total score.
Calculation[edit]
The HAS-BLED score is calculated as follows:
- Hypertension: 1 point
- Abnormal renal/liver function: 1-2 points
- Stroke: 1 point
- Bleeding history or predisposition: 1 point
- Labile INR: 1 point
- Elderly (age >65 years): 1 point
- Drugs/alcohol concomitantly: 1-2 points
A score of 0-1 indicates a low risk of major bleeding, while a score of 2 or more indicates a high risk.
Clinical Use[edit]
The HAS-BLED score is used to guide anticoagulation therapy in patients with AF. A high score may indicate a need for more frequent monitoring or a reconsideration of the risks and benefits of anticoagulation therapy. However, it should not be used in isolation to withhold anticoagulation in patients with a high risk of stroke.
Limitations[edit]
While the HAS-BLED score is a useful tool, it has some limitations. It does not account for all possible risk factors for bleeding, and it may overestimate the risk in some patients. Furthermore, the score has not been validated in all patient populations.
See Also[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Sponsored Health Resource
W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
